System and method for managing a patient

ABSTRACT

A system for managing a patient is disclosed and can include a patient interface adapted to obtain ultrasound information about the patient, a provider interface adapted to facilitate communication between the system and a provider, and a controller in communication with the patient interface and the provider interface, the controller including a clinical management module adapted to receive the ultrasound information and to recommend a clinical management strategy based upon the ultrasound information. A method of presenting a clinical management strategy is also described including obtaining information regarding a condition of a patient, developing a determinant reflecting the condition, and presenting a user with a clinical management strategy on an output device.

CROSS REFERENCE TO RELATED CASES

This application is a continuation application of U.S. application Ser.No. 12/536,247 filed Aug. 5, 2009, which application claims priority toU.S. Provisional Application 61/086,254, which was filed on Aug. 5,2008, and U.S. Provisional Application 61/224,621, which was filed onJul. 10, 2009, each entitled System (apparatus and method) to guideclinical hemodynamic management of patients requiring anesthetic care,perioperative care and critical care using cardiac ultrasound. Thepresent application also claims priority to U.S. Provisional Application61/140,767, which was filed on Dec. 24, 2008 and entitled PeripheralUltrasound System (apparatus and method) for automated and uninterrupteddata acquisition. The disclosures of each of the aforementionedapplications are hereby incorporated by reference herein in theirentireties.

FIELD OF THE INVENTION

The present disclosure relates to patient management. More particularly,the present disclosure relates to monitoring, responding to, andreporting on patient conditions. Even more particularly, the patientconditions can relate to circulatory function or hemodynamic status.

BACKGROUND

Proper circulatory function is essential to sustain and prolong life.From a more practical standpoint, circulatory function can be a factoraffecting health care costs resulting from complications, hospitalreadmissions, and mortality. According to some professionals, ensuringthe adequacy of circulatory function is one of the most importantclinical goals of healthcare providers for anesthetic, perioperative, orcritical care procedures. Currently, the American Society ofAnesthesiology (ASA) endorses the use of the EKG monitor, systemic bloodpressure (BP), pulse oximeter, and urine output (UO), known as theconventional parameters, as the basic standard of care for assessingcirculatory function. However, these conventional parameters may notalways provide suitable information for managing circulatory function.

Using conventional parameters may be clinically acceptable for patientswith normal cardiovascular function. However, conventional parametersoften provide incomplete information for patients with cardiovascularrisk factors and/or comorbidities. For example, in surgical and criticalcare settings, managing the circulatory function of a congestive heartfailure (CHF) patient with conventional parameters can lead apractitioner to deliver inappropriate amounts of intravenous (IV) fluidand/or maintain an inappropriate level of blood pressure leading tovolume overload of the circulatory system of the patient. As a result ofthe incomplete information, many patients currently undergoing surgicalprocedures and/or requiring critical care medicine may not receiveoptimal hemodynamic management. This can lead to cardiovascularcomplications, hospital readmission, and/or mortality. This result isboth detrimental to the health of the patient and costly to the healthcare system.

This weakness in the standard of care is exacerbated by the fact thatCHF, with normal or reduced contractile function, is the leadingadmission diagnosis for medicine and cardiology services in the UnitedStates. Further adding to the problem is that diastolic dysfunction,often the underlying cause of CHF, is common among the baby boomerpopulation. For individuals over 65, 53.8% suffer from some degree ofdiastolic dysfunction. (40.7% mild and 13.1% moderate or severe). Thenumber of individuals over 65 has been projected to increase by 50% from2000 to 2020 and as a result, the baby boomer population is recognizedas a driving force for healthcare services.

Conventional circulatory function parameters may provide incompleteinformation for patients with cardiovascular risk factors and/orcomorbidities. CHF is an example of one of those conditions and is alsoa common condition among the baby boomer population and the populationas a whole. The health related and economic costs associated withcomplications, readmissions, and mortality rates need to be addressed.Accordingly, there is a need for a more capable system for managing thehemodynamics of patients.

SUMMARY

In one embodiment, a system for assisting a provider in managing apatient may include a patient interface adapted to obtain ultrasoundinformation about the patient. The system may also include a providerinterface adapted to facilitate communication between the system and theprovider. The system may include a controller in communication with thepatient interface and the provider interface, the controller including aclinical management module adapted to receive the ultrasound informationand to recommend a clinical management strategy based upon theultrasound information.

In another embodiment, a method of presenting a clinical managementstrategy for a patient may include obtaining ultrasound informationregarding a condition of the patient from an ultrasound probe,communicating the ultrasound information to a controller incommunication with the ultrasound probe, employing the controller todevelop from the ultrasound information a determinant reflecting thecondition of the patient, and providing on an output device incommunication with the controller a clinical management strategy basedon the determinant.

In another embodiment, a method of developing a cardiovasculardeterminant of a patient, may include receiving ultrasound informationfrom a patient interface, the patient interface being adapted to obtainultrasound information related to cardiovascular function status of thepatient, processing the ultrasound information to determine thecardiovascular function status of the patient, and sending the status toa clinical management module for the development of a clinical strategy.

In another embodiment, a method of suggesting a clinical managementstrategy may include comparing a first order data point to a pluralityof categories, where the first order data point is associated withultrasound information, assigning a category from the plurality ofcategories to the first order data point based on which category of theplurality of categories, the first order data point falls, selecting arecommended intervening measure based on the assigned category, andpresenting the recommended intervening measure on a display.

In another embodiment, a method of managing a patient may includepositioning ultrasound probes on a patient, the ultrasound probes beingin communication with a controller, using an input device to instructthe controller to obtain cardiovascular function information from thepatient via the ultrasound probes, reviewing a suggested clinicalmanagement strategy, the strategy including a recommended interveningmeasure and being based on the cardiovascular function information,deciding whether to conduct the recommended intervening measure, adifferent intervening measure, or no intervening measure.

In another embodiment, a method of monitoring a patient may includemonitoring a patient via ultrasound and generating information from theultrasound. The method may also include, based upon the information,recording a clinical finding and recommending and recording anintervening measure, displaying a list of clinical findings includingthe clinical finding and related clinical findings, prompting a user toselect from the list of clinical findings, displaying a list ofintervening measures including the intervening measure and relatedintervening measures, prompting the user to select from the list ofintervening measures, compiling a report including the selected clinicalfinding and the selected intervening measure.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows a system for managing a patient according to certainembodiments.

FIG. 2 is a schematic cross-sectional view of a probe according tocertain embodiments.

FIG. 3 is a schematic view of an external imaging plane mechanism.

FIG. 4 is a schematic view of an internal imaging plane mechanism.

FIG. 5 is a side view of a probe according to certain embodiments.

FIG. 6 is a top view of a probe positioned on a patient according tocertain embodiments.

FIG. 7 is a front view of a connecting pad according to certainembodiments.

FIG. 8 is an isometric view of one embodiment of a connecting pad.

FIGS. 9 & 10 are each front views of a display according to certainembodiments.

FIG. 11 is a schematic view of a controller according to certainembodiments.

FIG. 12 is an exemplary 2D black and white ultrasound image displayaccording to certain embodiments.

FIG. 13 is an exemplary color Doppler image display according to certainembodiments.

FIG. 14 is and exemplary spectral Doppler image display according tocertain embodiment.

FIG. 15 is a chart showing categories for statuses of severalcardiovascular determinants according to certain embodiments.

FIGS. 16-27 are each charts reflecting clinical management strategyprocesses according to one or more embodiments.

FIG. 28 is an exemplary report input screen for use in preparing areport.

FIG. 29 is an exemplary report.

FIG. 30 is an exemplary list of an international classification ofdiseases for use in preparing a DRG report.

FIG. 31 is an exemplary DRG report.

FIG. 32 is an exemplary professional billing report.

FIGS. 33-36 are each charts reflecting steps taken to obtain patientinformation according to certain embodiments.

FIG. 37 is a chart showing steps taken by a hemodynamic managementsystem to assist in managing a patient according to certain embodiments.

FIG. 38 is a chart showing a method of presenting a clinical managementstrategy for a patient.

FIG. 39 is a chart showing a method of developing a cardiovasculardeterminant of a patient.

FIG. 40 is a chart showing a method of suggesting a clinical managementstrategy.

FIG. 41 is a chart showing a method of managing a patient.

FIG. 42 is a chart showing a method of monitoring a patient.

DETAILED DESCRIPTION

The present disclosure relates to a hemodynamic management system. Thesystem can be an ultrasound based system capable of non-invasivemonitoring of circulatory function including cardiac output and fillingpressures. The system can be used for live monitoring of patients in aclinical setting. The system can also be used for patients undergoinganesthetic, perioperative, critical care, or other procedures and canassist in developing clinical management strategies. The live monitoringmay allow providers in this setting to obtain circulatory functioninformation previously limited to a diagnostic ultrasound setting.Access to this information in these procedural settings may allowproviders to actively manage patients' circulatory function during aprocedure. Moreover, the hemodynamic management may be more suitablethan that which was available with the conventional parameters describedabove.

Referring now to FIG. 1, a system is shown including a patient interface100, a controller 102, a provider interface 104, an auxiliary deviceinterface 106, and a network interface 108. The system can preferably bea hemodynamic management system where the patient interface 100 includesone or more probes 110, the controller 102 is a hemodynamic controller,and the provider interface 104 is an input and/or output device orsystem. The hemodynamic management system can allow the controller 102to access circulatory information relating to a patient through thepatient interface 100 and the provider interface 104 can be used tofacilitate the activities of the controller 102 and to receive outputinformation from the controller 102. In a preferred embodiment, theauxiliary device interface 106 may function to interface with devicesrelated to conventional parameters such as an EKG or a blood pressuremonitor, but other devices may also be connected through the auxiliarydevice interface 106. The network interface 108 can function,preferably, for use in remote supervision or quality assessment, but maybe adapted for other types of network communication and datatransmission.

The patient interface 100 can include one or more probes 110 adapted tobe positioned on a patient and adapted to obtain information about apatient. Preferably, the probes 110 can be adapted to obtain circulatoryfunction information about a patient. The probes 110 can be in the formof a transducer adapted to alternate between sending and receivingsignals. For example, in a preferred embodiment the probes 110 can beultrasonic transducers adapted to intermittently or continuously produceand detect ultrasonic waves.

The probes 110 can be positioned on a patient in a suitable locationrelated to the information desired to be collected by any given probe110. In a preferred embodiment, the probes 110 can be adapted to gatherinformation relating to the hemodynamic status of a patient. In thisembodiment, the probes 110 can be positioned in suitable locations forgathering information about the heart and may be referred to herein ascardiac probes 110. Accordingly, the probes 110 can be placed in one ofseveral available windows. A window can be defined as a transducerlocation from where the heart can be imaged using ultrasound-basedimaging and the windows can be external or internal to the patient'sbody. In a preferred embodiment, four external cardiac probes 110A-D canbe provided and can be positioned in the transthoracic parasternalwindow, the transthoracic apical window, the sub-costal window, and thesuprasternal notch window, respectively.

The transthoracic parasternal window can be defined as being located onthe left side of the sternum between the 3^(rd) and 4^(th) rib. Thetransthoracic apical window can be defined as being located on the chestbetween the 5^(th) and 6^(th) left ribs posterior and lateral to thenipple line. The sub-costal window can be defined as being located underthe right costal ridge and directed toward the left shoulder. Thesuprasternal notch window can be defined as being located at thesuprasternal notch.

Preferably, an internal cardiac probe 110E can also be provided in themid-esophageal window and thus can be positioned midway down theesophagus. In the preferred embodiment, a sixth probe 110F can beincluded in the form of an external non-cardiac probe 110. The sixthprobe 110F can be adapted to image superficial non-cardiac structuresoutside the chest.

Additional or fewer probes 110 can be provided. The probes 110 can allbe of the same type or they may differ and combinations of probe type orstyle can be included. Preferably the probes 110 can all be ultrasonictransducers. Alternatively, some of the probes 110 may include pressure,electrical signal, or temperature sensors in lieu of ultrasonictransducers and other probe types can be provided.

Referring to FIG. 2, in a preferred embodiment, the four externalcardiac probes 110A-D are ultrasonic transducers. The probes 110A-D canhave a relatively low profile with a height 111 of between approximately1 cm to approximately 10 cm. Preferably, the height 111 is betweenapproximately 2 cm to approximately 8 cm. The probes 110A-D can have asurface contact area of approximately 1 cm to 3 cm by approximately 3 cmto 8 cm, or approximately 3 to 24 cm². Preferably, the contact area isapproximately 2 cm by approximately 5 cm, or approximately 10 cm².

In a preferred embodiment, the internal cardiac probe 110E is also anultrasonic transducer. The probe 110E can be approximately 1 cm to 2 cmby approximately 2.5 cm to 3.5 cm, or approximately 2.5 to 7 cm².Preferably, the internal cardiac probe 110E is approximately 1.5 cm by 3cm, or approximately 4.5 cm².

In a preferred embodiment, the external non-cardiac probe 110F can alsobe an ultrasonic transducer with a higher frequency than the cardiacprobes 110A-E and thus adapted for imaging more superficial structures.For example, the external non-cardiac probe 110F may be used to identifysuperficial vascular structures outside the chest. As used herein,superficial can be understood to mean less than approximately 12 cmunder the skin or preferably less than 10 cm under the skin. The probe110F can be used when inserting a central line or a peripheral venous orarterial catheter. Alternatively or additionally, the probe 110F can beused for identifying large nerve bundles of the neck or an upper orlower extremity when performing a peripheral nerve blockade for surgicalor post-operative pain control. The external non-cardiac probe 110F canhave a height of between approximately 1 cm to approximately 12 cm.Preferably, the height is between approximately 2 cm and 8 cm. Theexternal non-cardiac probe 110F can have a surface contact area ofapproximately 1 to 3 cm by approximately 8 to 10 cm, or approximately 8to 30 cm². Preferably, the external non-cardiac probe 110F has a contactarea of 2 cm by 8 to 10 cm, or 16 to 20 cm².

In a preferred embodiment, each of the external or internal probes 110can be adapted for obtaining information suitable for two-dimensionalimaging, three-dimensional imaging, B-mode, M-mode, color Doppler, andspectral Doppler output. The probes 110 can be built with piezo-electriccrystals 113 adapted to emit ultrasonic signals. The probes 110 caninclude a suitable crystal array. For example, the cardiac probes 110can be constructed with a phased array of crystals or a matrix of aphased array of crystals. The phased array of crystals may provide for atwo dimensional pie-shaped cross-sectional image. The matrix may providefor a three dimensional image. The probes 110 adapted to image moresuperficial elements can be constructed with a linear array of crystalsallowing for higher frequency imaging and may provide for a rectangularimage. Other arrangements of crystals such as, for example, a circulararray can be used and are within the scope of the disclosure. Moreover,mechanical transducers could be used in lieu of or in addition to thepiezo-electric crystal type transducers described. In other embodimentsthe probes 110 can be adapted to obtain other information such astemperature, pressure, moisture, EKG signals, electrical signals, orother information indicative of patient condition. Accordingly, theprobes 110 can take the form of a thermometer or a pressure transduceror sensor. The probes 110 can monitor other conditions and can take theform of other suitable devices adapted to detect and/or measure acondition.

Referring generally to FIGS. 3 and 4, the probes 110 can include avariable probe view. In a preferred embodiment, the probe view can beadjusted with an imaging plane mechanism 112 allowing each probe 110 ofthe system to acquire optimal quality images with minimal or nointervention by the provider. The mechanism 112 can be adapted to allowfor adjustment of the imaging plane of the probe 110 by providing arotation angle adjustment and an elevation angle adjustment. In someembodiments, this mechanism 112 may be external and thus the imagingplane may be manually adjustable through physical adjustment of knobs,pins, levers, or other mechanical adjustment features. In otherembodiments, the mechanism 112 may be internal and the imaging plane maybe adjustable automatically by the controller 102 or manually throughprovider interaction with the controller 102.

In another embodiment, the patient interface 100 can include a housing114 enclosing the probe 110 and the probe 110 can be adjustable withinthe housing 114. In this embodiment, the variable imaging planemechanism 112 results from the interaction of the probe 110 with thehousing 114. For example, the probe 110 can be rotatably positionedwithin the housing 114 about an axis substantially orthogonal to thepatient body surface. The housing 114 may include an upper half and alower half slidably connected about a circular perimeter allowing theupper half to rotate relative to the lower half. The probe 110 may beconnected to the upper half allowing for the rotation of the probe 110via rotation of the upper half relative to the lower half. The probe 110can alternatively or additionally be pivotal about an axis substantiallyparallel to the patient body surface. The probe 110 may be positioned ona pivot rod extending from the housing 114 where the pivot rod ispivotally connected to the housing 114. The pivot rod may include apivot knob for adjusting the pivotal position of the pivot rod therebyadjusting the pivotal position of the probe 110. In other embodiments,the probe 110 can be slidably positioned within the housing 114 allowingthe probe 110 to translate in one or more directions parallel to thepatient body surface. The probe 110 can be adapted to move in adirection relative to the housing 114 allowing for adjustability of thesignal being emitted and/or received from the probe 110.

As shown in FIG. 3, an exemplary external imaging plane mechanism 112 isshown. As shown, the probe 110 may include a connecting pad 116, ahousing 114 allowing for rotation of the transducer in a planesubstantially parallel to the patient surface, and a lateral side bar118 for pivoting the transducer in elevation. The external imagingmechanism 112 may be adjusted automatically with a series of controlledactuators and/or the system may be adjusted manually. In FIG. 4, anexemplary internal imaging plane mechanism 112 is shown. The mechanism112 includes a rotation pulley 120 and cable 122 for rotating thetransducer in a plane substantially parallel to the patient surface andan elevation pulley 124 and cable 126 for pivoting the transducerrelative to the patient surface. As with the external mechanism 112, theinternal mechanism 112 may be adjusted automatically and/or manually.

Referring to FIGS. 5-8, the probes 110 of the patient interface 100 canbe positioned on a patient and connected to the patient with a securingsystem. The securing system can include a connecting pad 116 and theprobe 110 can be affixed to the connecting pad 116. Alternatively, theconnecting pad 116 can be omitted and the probe 110 can be adhered orexternally secured directly to the body surface. Additionally, thesecuring system can include a probe detection device 128 adapted totrigger activation and calibration of an attached probe 110. As shown,the probe 110 can be connected to the controller 102 with a lead 115.

Referring particularly to FIG. 8, the connecting pad 116 can be anelastomeric material such as rubber or foam rubber. Preferably, theconnecting pad 116 can be a latex free elastomeric material. Theconnecting pad 116 can include a single layer or multiple layers. Theconnecting pad 116 can include an aperture 130 for receiving a distalend of the probe 110. The aperture 130 can extend fully through theconnecting pad 116 or can extend partially through the pad 116 as shown.Where the aperture 130 extends fully through the connecting pad 116, adistal end of the probe 110 can be placed in direct contact with thepatient body surface through the aperture 130. Preferably, the contactbetween the probe 110 and the body surface is free of air voids. In someembodiments, an ultrasonic gel 131 can be provided between the probe 110and the patient body surface as shown in FIG. 2. Where the aperture 130extends partially through the connecting pad 116, the portion of the pad116 between the probe 110 and the body surface can be solid or a liquidultrasonic gel type material. Preferably, the portion of the pad 116between the probe 110 and the body surface is free of voids or airpockets.

The probe detection device 128 can be integrated into the connecting pad116. The device 128 may be adapted to sense that a probe 110 isconnected to the pad 116 and may further be adapted to triggeractivation and calibration of the probe 110. The probe detection device128 can be in electrical and/or data communication with the controller102 and can thus signal the controller 102 when a probe 110 is present.This communication may be facilitated through contact with the probe110. That is, the device 128 may not be in communication with thecontroller 102 unless or until the probe 110 is attached to theconnecting pad. Alternatively or additionally, the device 128 may be indirect communication with the controller 102 via a wired or wirelessconnection. In a preferred embodiment, the probe detection device 128can be an electronic chip embedded in the connecting pad 116. The chipcan include a contact or other sensing mechanism, such as a pressuresensor, for sensing the attachment of a probe 110 to the connecting pad116. Upon attachment of a probe 110, the chip may be configured tosignal the controller 102 to activate and calibrate the attached probe110. In some embodiments, the connecting pads 116 may be adapted for useat a particular position or window. In these embodiments, the chip ofthe probe detection device 128 may be designed, configured, or otherwiseadapted to indicate its position to the controller 102 such that theattached probe 110 can be activated and calibrated for a particularposition on the patient.

The connecting pad 116 can be secured to the patient with a securingsystem. Preferably, the securing system is an adhesive and morepreferably is a biocompatible adhesive. Alternatively or additionally,the connecting pad 116 can be connected to the patient with an externalsystem in the form of a superimposed layer of adhesive material. Forexample an oversized piece of tape can be positioned over the probe 110and the connecting pad 116 to secure the assembly to the patient. Thesuperimposed adhesive material could alternatively include a centralaperture for receiving the probe 110 so as to secure the connecting pad116 to the body surface without covering the probe 110. The superimposedadhesive material can include a slit or slot through the portion of thematerial around the aperture to allow the material to be positionedaround the lead 115 extending from the probe 110 and allowing thematerial to be easily removed and replaced. In yet another alternative,the external system can be one or more bands, belts, or strapspositioned to secure the probe 110 and/or connecting pad 116 to thepatient's body surface. The external system can extend around thepatient's body and be drawn tight or connect to a supporting table inthe form of a tie-down. The external system can extend across thesurface of the probe 110 and/or connecting pad 116 or it can be securedto the probe 110 and/or connecting pad 116 via a hook, a loop, a button,a hook and loop system, or some other securing mechanism. The externalsystem can connect to itself with any or a combination of any of theabove listed connections.

The patient interface 100 can be in data communication with thecontroller 102 via a lead 115, in the case of a wired connection, or thepatient interface 100 can be in wireless data communication with thecontroller 102. Where a wired connection is provided, the connection caninclude power flowing to the patient interface 100 from the controller102 or the patient interface 100 can includes its own power source.Where wireless communication is provided, the patient interface 100 caninclude its own power source. The power source, in either a wired orwireless condition, can include probe specific batteries, or an overallpatient interface battery connected to all of the probes 110.

The probe or probes 110 can be the same or similar to the probedescribed in U.S. Provisional Patent Application No. 61/140,767 filed onDec. 24, 2008 entitled Peripheral Ultrasound system (apparatus andmethod) for automated and uninterrupted data acquisition. The probe orprobes 110 can alternatively be the same or similar to the devicedescribed in U.S. Pat. No. 5,598,845 to Chandraratna et al. The probe orprobes 110 can alternatively be the same or similar to the devicedescribed in U.S. Pat. No. 6,261,231 to Damphousse. The probe or probes110 may alternatively include features and combinations of any or all ofthe above disclosures.

Referring now to FIGS. 9-10, a provider interface 104 is shown. Theprovider interface 104 can include one or more provider output devicesand one or more provider input devices. Regarding the provider outputdevices, a display 132 in the form of a cathode-ray tube (CRT), liquidcrystal display (LCD), Plasma based display, or another type of display132 can be provided. The provider output device can also include aprinter and can include a speaker for transmitting sound type output inthe form of tones or verbal output.

In a preferred embodiment, the display 132 may be large enough topresent clear ultrasound images and image acquisition sequencing. Forexample, the display 132 may be adapted to present four digital loops atthe same time as shown in FIG. 10. More or fewer loops can also beprovided. The display 132 may also be adapted for displaying an EKGsignal or a blood pressure value. In one embodiment, the display 132 canshow a value for continuous left-sided cardiac output. For example, thedisplay 132 may read 5 Liters/min. Additionally, consideration can begiven to the workspace of the provider and as such, the display 132 canbe similar in size to a monitor display on an EKG or a blood pressuremonitor. Other output type devices may be provided.

Regarding the input devices, a keyboard, mouse, or joystick can beprovided. Additionally, a touchpad can be included or a microphone forreceiving an audio type input can be provided. In a preferredembodiment, the display 132 output device can double as an input devicevia a touch screen for receiving input information from the provider.Alternatively or additionally, the display 132 may include buttons orswitches as shown in FIGS. 9 and 10. Other input devices can also beused.

Referring to FIG. 11, the auxiliary device interface 106 can include oneor more ports on the controller 102 for connection of the auxiliarydevices. The ports can be any suitable plug-type socket on thecontroller 102 for receiving a lead from an auxiliary device.Alternatively, the auxiliary device interface 106 can be a wirelessbased interface for receiving input information from an auxiliarydevice.

Still referring to FIG. 11, the network interface 108 can include one ormore jacks on the controller 102 for connection to a network. This jackcan be any suitable connection socket on the controller 102 forreceiving a network cable for connection to a near by network jack. Forexample, an Ethernet connection jack, USB port, or phone jack may beprovided. Other suitable connection systems can be provided. The networkinterface 108 can also include a wireless based interface forcommunicating with a wireless network.

Referring still to FIG. 11, a controller 102 is shown. The controller102 can include a computer adapted to connect and control severalinterfaces. Alternatively, the controller 102 can be more particularlyconstructed for a particular process or purpose. The controller 102 canbe in the form of a field programmable gate array, a mixed signal microcontroller 102, an integrated circuit, a printed circuit board, or thecontroller 102 can be created in a virtual product development platformsuch as LabVIEW or the like. Accordingly, the controller 102 can includeany combination of hardware and software and can be adapted for aparticular purpose.

Processes and analyses performed by the controller 102 can be performedby modules including hardware, software, or some combination of hardwareand software. In a preferred embodiment, the controller 102 includes apatient interface module 134, an analysis module 136, and a providerinterface module 138. The provider interface module 138 may furtherinclude a clinical management module 140, an electronic reporting module142, and a Diagnosis Related Group (DRG) reporting module 144. Othermodules can be included and can be adapted for receiving, sending,interpreting, or analyzing data and any combination of processes canalso be included in any given module.

The controller 102 can include hardware and/or software to interact withand control any or all of the several included modules and/orinterfaces. Moreover, any combination of the software, hardware, and/ormodules is within the scope of the present disclosure. Accordingly,complete or partial overlap of the functionality of the modules shouldbe understood to exist in certain circumstances.

The controller 102 can include a patient interface module 134 adapted tocontrol the patient interface 100. More particularly, the patientinterface module 134 can be adapted to drive the probes 110. In apreferred embodiment, the patient interface module 134 may include animage generating module 146. The image generating module 146 can beadapted to control ultrasonic transducers and can be adapted togenerate, transmit, and receive ultrasonic waves via the transducers.Accordingly, the image generating module 146 can perform beamforming,array beamforming, and all signal processing functions. The imagegenerating module 146 can produce two-dimensional and three-dimensionalimaging as well as B-mode, M-mode, color Doppler, and spectral Dopplerdata points. In the case of alternative or additional types of probes110, the patient interface 100 can be adapted to initiate suitable probesignals and/or receive probe data.

In addition, the patient interface module 134 can control the adjustmentof the probe view. That is, where the probe 110 is adjustable relativeto its position on the patient, the patient interface module 134 cancontrol actuation devices for rotating, pivoting, translating, orotherwise adjusting the position and probe view obtained by the probe110. Alternatively or additionally, the adjustment of the probes 110 maybe manually performed with knobs or other physical adjustment devices.

The patient interface module 134 can be adapted to periodically orcontinuously collect data via the probes 110 of the patient interface100. In a preferred embodiment, the patient interface module 134 canautomatically acquire ultrasound-generated data points at a selectedtime interval. For example, the patient interface module 134 can be setby the provider to obtain cardiovascular information about a patientevery minute, every two minutes, every 10 minutes, or at any timeinterval selected by a provider.

The patient interface module 134 can also be adapted to control themanner in which the probes 110 collect the data. That is, the patientinterface module 134 can select from one or more modes for any givenprobe 110 to use when collecting information. For example, a first modeof data collection may include a two-dimensional (2D) black and whiteimage of the moving heart muscle and valves, as shown in FIG. 12. Inthis mode, one or more heart beat cycles may be acquired for each 2Dimage cross-section. The heart beat cycles can be shown on the display132 in a video loop format called a 2D clip such that the heart looks tobe beating continuously. A second mode of data collection may includecolor Doppler imaging. This mode may also include a region of interest(ROI) box superimposed on a 2D ultrasound image. The ROI box may bedefined by the provider by clicking and dragging a mouse to form a box.Other known methods of selecting a box may be used and other shapesother than a box may also be used. Within the ROI, the velocity anddirection of the blood flow during a cardiac cycle may be shown using arange of shades of blue and red colors. The blue and red colors mayreflect the direction of flow toward or away from the probe 110. (i.e.,red being toward the probe 110 and blue being away from the probe 110.)In FIG. 13, the blood flow is toward the probe and would appear on acolor display in red. Similar to the first mode, this mode may also beshown on the display 132 in a video loop format. A third mode of datacollection may include spectral Doppler tracings. Similar to the secondmode, this third mode may also use a ROI defined by the provider. Thespectral Doppler may measure and display the direction and velocity ofthe blood flow within the ROI as shown in FIG. 14. The spectral Dopplermode allows calculation of clinically useful volumes, flows, andpressures using the measured velocities.

After imaging and acquisition, all ultrasound-generated data may berecorded and stored in a memory of the controller 102. Alternatively oradditionally, the data may be directly communicated to the analysismodule 136 for further processing. The memory of the controller 102 maybe a digital memory of a hard drive where a computer system is providedas the controller 102. Other memory types can be used. Theultrasound-generated information can allow for determination of theassessment of ventricular contractility, valvular structure andfunction, cardiac output and filling pressures.

The controller 102 can also include an analysis module 136. The analysismodule 136 can be adapted for use with a specific type of probe 110 orit may be a more general module adaptable for use with several, and/ordiffering types, of probes 110. The analysis module 136 can useinformation received from the probes 110 and can process thatinformation into additional data or results.

In a preferred embodiment, the analysis module 136 can be adapted foruse with ultrasonic transducer type probes 110. The analysis module 136can include one or more algorithms configured for analyzing thecirculatory function information obtained by the transducers and fordeveloping cardiovascular determinants. These algorithms may includeinterpretive processes or more calculated processes depending on theinformation received and the determinants being developed. As discussedabove, the information received may be provided in one of at least threeforms including: a) 2D or 3D black and white images b) Color Dopplerimages, and c) Spectral Doppler tracings. The determinants beingdeveloped and used for monitoring patients can include: contractilefunction, valvular function, cardiac output, and filling pressures.

These determinants can be developed by the analysis module 136 throughinterpretation of one or more types of ultrasound-generated imagesand/or calculations based on ultrasound data. In some cases, for examplethe cardiac output, the development of the determinant may be asubstantially calculated process. However, in other cases, for examplethe contractile function, the development of these determinants may be asubstantially interpretive process. For example, determining whether thecontractile function is normal requires knowledge of how a normalcontracting heart appears. Accordingly, this interpretive process mayinclude comparing a captured image clip to image clips with known valuesor categorizations. Image recognition software may be employed forcomparing the captured clip to a series of stored clips. A correlationalgorithm for making the comparison may be based on previously definedvisual assessment pattern correlations, where the visual assessment wasperformed by clinical diagnostic experts in cardiac ultrasound imagingand the clinically adequate and relevant correlation is made possible byevaluating and computing a large number of cases and images.Alternatively or additionally, where the provider is viewing the display132, the provider may interpret the image or may compare the image tothe database of images. Accordingly, the provider may develop thedeterminants separate from and/or in addition to the system.

In one embodiment, the correlation algorithm may include analyzing acaptured image clip with an image recognition module 148 and may furtherinclude comparing the result to a series of stored image clips in adatabase. Each of the stored image clips in the database may be assignedto a category based on previous clinical studies as discussed above. Arating may be given to the comparison of the captured image clip to arespective stored image clip for each comparison made. The captured clipmay be compared to all of the stored clips and a category may beassigned to the captured image clip consistent with those image clips towhich the comparison had the highest ratings. Alternatively oradditionally, a trend of a likeness to a given category of stored clipsmay be recognized and a category may be assigned accordingly. In eithercase, the captured image clip may be categorized consistent with thestored image clip or clips that it most closely resembles. Otheralgorithms may be followed to correlate a captured image clip with acategory of clips in a database and these other algorithms are withinthe scope of the present disclosure.

Regarding the contractile function, the analysis module 136 can developboth right and left contractile function information by analyzing a 2Dand/or 3D captured image clip provided by the patient interface 100. Thecaptured image clip can be compared to image clips in a contractilefunction image clip database and a category may be assigned to thecaptured image clip as shown in FIG. 15. Accordingly, the correlationalgorithm may be used to categorize the acquired 2D image clip into a a)hyperdynamic, b) normal, c) moderately reduced, or d)severely reducedventricular contractile function pattern.

Regarding the valvular function, the analysis module 136 can provide anassessment of the presence and severity of mitral, aortic, and tricuspidvalve regurgitation by analyzing color Doppler images. A color Dopplerimage clip of these valves can be captured by the patient interface 100.The analysis module 136 can compare the image to image clips inrespective mitral, aortic, and tricuspid image clip databases. Acategory can be assigned to the captured image clip for each valve.Accordingly, the correlation algorithm can be used to categorize thevalvular function of each valve as shown in FIG. 15. For the mitralvalve, the algorithm may categorize the captured image clip into a a)mild, b) moderate, or c) severe mitral regurgitation pattern. For theaortic valve, the algorithm may categorize the captured image clip intoa a) mild, b) moderate, or c) severe aortic regurgitation pattern. Forthe tricuspid valve, the algorithm may categorize the captured imageclip into a a) mild, b) moderate, or c) severe tricuspid regurgitationpattern.

Regarding the cardiac output and filling pressures, the analysis module136 can utilize spectral Doppler tracings to determine these and otherrelated values. For example, spectral Doppler can be used by theanalysis module 136 to provide a basic assessment of the leftventricular diastolic function, the left ventricular filling pressure,the systolic pulmonary artery pressure, the presence and severity ofaortic stenosis, and the cardiac output.

Regarding diastolic function, a spectral Doppler tracing relating to themitral inflow (i.e., the mitral inflow tracing) can be used to obtain animage clip with the patient interface 100. The captured clip can becompared to stored clips in a diastolic dysfunction image clip databaseand a category can be assigned to the captured image clip as shown inFIG. 15. Accordingly, the captured image clip can be categorized into aa) mild, b) moderate, or c) severe diastolic dysfunction pattern.

Regarding the left ventricular filling pressure, a general fillingpressure determinant can be developed using a spectral Doppler tracingrelating to the pulmonary venous flow. A captured image can be obtainedof the spectral Doppler tracing using the patient interface 100, acomparison can be made to a database of filling pressure image clips,and a category can be assigned to the captured clip as shown in FIG. 15.Accordingly, the captured clip can be categorized into a a) normal or b)elevated left ventricle filling pressure pattern. Alternatively oradditionally, the filling pressure can be estimated by calculating theratio between two spectral Doppler direct measurements. The peakvelocity of the E wave of the mitral inflow and of the e′ mitral annuluswave of the tissue Doppler may be directly measured using spectralDoppler. The ratio of the E wave velocity to the e′ mitral annulus wavevelocity can provide a numerical estimate of the left ventricularfilling pressure. Once calculated, the filling pressure can benumerically compared to known normal pressures. For example,approximately 5-15 mm Hg may be considered normal and values above orbelow this range may be deemed high or low respectively.

Regarding the systolic pulmonary artery pressure, a spectral Dopplertracing of the velocity of the red cells of the systolic tricuspidregurgitation jet may be obtained by the patient interface 100. A directmeasurement of the peak velocity may provide a clinically relevantestimation of the systolic pulmonary artery pressure using thesimplified Bernoulli equation. The normal range of the systolicpulmonary artery pressure may be less than 30 mm Hg.

Regarding mitral and aortic stenosis, direct measurements may be made ofspectral Doppler tracings to develop these determinants. For mitralstenosis, the mean gradient of pressure may be directly measured fromthe spectral Doppler tracing of the mitral inflow and the severity ofmitral stenosis may thus be defined as either a) mild (mean gradient of5 mm Hg), b) moderate (>5 and <15 mm Hg), or c) severe (>15 mm Hg.) Foraortic stenosis, the peak velocities may be directly measured from thespectral Doppler tracing of the red cells in the left ventricularoutflow tract (LVOT) and at the aortic valve. The ratio of the peakvelocities of the red cells in the LVOT to those at the aortic valve maydefine the severity of aortic stenosis as either a) mild if the ratio is1:2, b) moderate if the ratio 1:3, or c) severe if the ratio is 1:4.

Regarding the cardiac output, two direct measurements may lead to thedevelopment of this determinant. The profile of the spectral Dopplertracing obtained from the LVOT during systole may be used to determinethe average distance red cells travel during this event. That is, thearea under the spectral Doppler tracing, or the integral of the tracing,may provide this average distance. Additionally, the diameter of theLVOT may be directly measured allowing for the geometric calculation ofLVOT area. With those two data points, the average distance of red celltravel and LVOT area, the patient stroke volume and therefore thecardiac output can be calculated. A normal cardiac output may be from 5to 6 L/min.

The controller 102 can also include a provider interface module 138 forreceiving instructions from the provider and for displaying patientinterface 100 or analysis data. The provider interface module 138 caninclude software and/or hardware suitable for receiving and interpretinginformation from several input devices such as a mouse, keyboard, touchscreen, joystick, or other input devices. In the case of audio input,the provider interface may include a voice recognition software forinterpreting provider commands. The provider interface module 138 caninclude a display module 150 including software and/or hardware fordisplaying graphs, images, text, charts, or other displays for reviewand/or interpretation by a provider or other user. Other software and/orhardware can be provided for other output types such as printing. In apreferred embodiment, the display module 150 can include software and/orhardware for a series of menus accessible by the provider for producingreports, medical record data, billing information, and other outputtypes.

In a preferred embodiment, the display module 150 can be adapted forproducing image displays adapted to display anatomy scanned by theprobes 110. That is, the display module 150 can be adapted to show thedata obtained from the several modes of operation of the probes 110. Ina preferred embodiment, the probes 110 produce ultrasound data and theultrasound-generated data may be displayed on the monitor as standardultrasound images. As shown in FIGS. 10 and 12, the 2D cross-sectionimages may be black and white moving clips of the heart beating. Theimages may be looped video clips giving the end-user the appearance of acontinuous heart beating. As shown in FIG. 13, the color Doppler imagesmay be 2D cross-section images with a ROI color box superimposed on avalvular structure and showing the direction and velocity of the bloodflow based on the shade and color displayed. This image may also be alooped video clip showing the heart beating. As shown in FIG. 14, thespectral Doppler tracings may be still images displaying a graphicalrepresentation of the variation of the measured red cells velocitiesover time, usually one cardiac cycle. In another embodiment, the 2Dimages may be displayed as 3D images and provide the equivalentinformation on ventricular contractility and valvular structure andfunction.

The controller 102 can include a clinical management module 140. Theclinical management module 140 can be adapted to receive data from theanalysis module 136 and/or the provider interface module 138 and presentsuggested clinical strategies to the provider. The clinical managementmodule 140 can be based upon knowledge and studies conducted regardingsuitable clinical management of patients. For example, the clinicalmanagement module 140 can include suggested clinical strategies relatingto a particular system of the human body, such as the nervous system,digestive system, or circulatory system. The clinical management module140 can alternatively or additionally include suggested clinicalstrategies relating to particular organs or conditions. Strategiesrelating to other aspects of patients requiring clinical management canbe included and the clinical management module 140 can be directed toone or more of these aspects of patient management. Accordingly, theclinical management module 140 can be adapted to provide a menu or otherselection screen allowing for the focusing of the device for aparticular clinical management.

In a preferred embodiment, the clinical management module 140 can bedirected toward managing the anesthesia or hemodynamic status of apatient. Preferably, the clinical management module 140 can be adaptedfor use while the patient undergoes an anesthetic, perioperative, orcritical care procedure. Accordingly, the clinical management module 140can be adapted for use with the analysis module 136 and patientinterface 100 described above. The clinical management module 140 canreceive ultrasound or other data from the analysis module 136 andprovide a suitable clinical management strategy. Alternatively oradditionally, the data can be provided by the provider uponinterpretation of the ultrasound generated images and/or data.

In the preferred embodiment, the clinical management module 140 may usethe cardiac output and the left ventricular filling pressures as firstorder data points to manage a patient's hemodynamic status.Additionally, the clinical management module 140 may use the valvularfunction and the biventricular contractile function as second order datapoints to manage a patient's hemodynamic status. The clinical managementmodule 140 can assess the primary and/or secondary order data points andsuggest a suitable clinical strategy. The clinical strategy may suggestthe adjustment of one or more cardiovascular determinants. Inparticular, the strategy may suggest the adjustment of cardiovascularcontrol determinants such as the preload, the afterload, the heart rate,and the ventricular contractility. The clinical strategy can be followedby the provider or the provider may choose not to follow the strategy.

As shown in FIG. 16-25, the clinical management module 140 can includeone or more algorithms to be followed based upon the input informationprovided. Referring to FIG. 16, in clinical cases where the first orderdata points 200 indicate a low cardiac output 202 and high fillingpressure 204, the clinical management module 140 may suggest that theprovider reduce the preload 206 and reduce the afterload 208 (Strategy1). Referring to FIG. 17, where the first order data points 200 indicatea low cardiac output 202 and filling pressure 204 within normal limits,the module may suggest that the provider reduce the afterload 208 andmaintain the current preload 206 (Strategy 2). In FIG. 18, the firstorder data points 200 indicate a low cardiac output 202 and low fillingpressure 204 and the strategy suggests that the provider increase thepreload 206 (Strategy 3). In FIG. 19, the first order data points 200indicate a normal cardiac output 202 and high filling pressure 204 andthe strategy suggests that the preload 206 be reduced and that thesystemic blood pressure be maintained if within normal limits (Strategy4). The strategy may also suggest that the afterload 208 be reduced ifthe systemic blood pressure is high (Strategy 4). Referring to FIG. 20,where the first order data points 200 indicate a normal cardiac output202 and normal filling pressures 204, the strategy may be to maintainthe current preload 206 and afterload 208 conditions (Strategy 5). Asshown in FIG. 21, in clinical cases where the cardiac output 202 remainslow despite optimal preload 206 and afterload 208 management and thesecond order ultrasound-generated data points 210 indicate a reducedcontractile function 212, the strategy may be made to use inotropicsupport 214 (Strategy 6).

Referring now to FIG. 22, where the second order data points 210indicate mitral valve regurgitation 216, the strategy may be to reducethe afterload 208 and maintain a faster heart rate 220 and higherpreload 206 (Strategy 7). Where mitral valve stenosis 218 is indicated,the strategy may be to reduce the preload 206 and maintain a slowerheart rate 220 (Strategy 7). Referring to FIG. 23, where the secondorder data points 210 indicate aortic valve regurgitation 222, thestrategy may include reducing the afterload 208 and maintaining a fasterheart rate 220 and higher preload 206 (Strategy 8). As shown in FIG. 24,in clinical cases where the second order data points 210 indicate aorticvalve stenosis 224 with high filling pressures 204, the strategy maysuggest to reduce the preload 206 and maintain a slower heart rate 220(Strategy 9). As shown in FIG. 25, where the second order data points210 indicate aortic valve stenosis 224 with normal filling pressures,the strategy may be to maintain a slower heart rate 220 and the modulemay also include an indication that afterload 208 reduction is safe(Strategy 10).

Referring now to FIGS. 26 and 27, clinical management strategies areshown with additional detail. Moreover, these strategies are shown tointerface with a conventional parameter such as systolic blood pressure226. With reference to FIG. 26, where the first order data points 200indicate that the cardiac output 202 is low the clinical managementmodule 140 can then look to the additional first order data point,filling pressure 204, to determine which of two branches to follow fordetermining a clinical strategy. Where the filling pressure 204 is high,three additional branches are based upon systolic blood pressure 226.For a systolic blood pressure (BP) 226 greater than 120 mm Hg, theclinical strategy may suggest reducing the afterload by 15% and limitingintravenous fluid (IV) as required to keep the vein opened (KVO). For asystolic BP 226 of 90 to 120 mm Hg, the clinical strategy may suggestreducing the afterload by 10% and limiting the IV preload to KVO. For asystolic BP 226 less than 90 mm Hg, the clinical strategy may suggestlimiting the IV preload to KVO and to consider inotropic support.Similarly, where the filling pressures are normal, three additionalbranches also based on systolic BP 226 are shown. Where systolic BP 226is greater than 120 mm Hg the clinical management strategy may be toreduce the afterload by 15% and maintain basal IV fluid intake. For asystolic BP 226 of 90 to 120 mm Hg, the clinical strategy may suggest toreduce the afterload by 10% and maintain basal IV fluid intake. Wheresystolic BP 226 is less than 90 mm Hg, the clinical strategy may suggestlimiting the afterload reduction. A normal ejection fraction (EF) may beconsidered to be from 55% to 70% and in this case if the EF is greaterthan 40% the strategy may suggest that the provider consider an IV bolusof 250 ml. If the EF is less than 40%, the strategy may suggest that theprovider consider inotropic support and if there is no increase orminimal increase in Stroke volume (SV), the strategy may further suggestthat the provider consider an IV bolus of 100 ml.

A similar strategy to that shown in FIG. 26, is shown in FIG. 27 wherethe cardiac output 202 is normal. Here, the strategy differs from thatshown in FIG. 26, in the normal filling pressure 204 branch. That is, inthe normal filling pressure 204 branch, where the systolic BP 226 isgreater than 120 mm Hg, the strategy suggests an afterload reduction of10% in lieu of 15%. Also, for a systolic BP 226 of 90 to 120 mm Hg, thestrategy suggests maintaining the afterload and the basal IV intakelevels in lieu of reducing the afterload by 10% with maintained basal IVintake levels.

It is noted that the present disclosure is not to be limited to thespecific percentages of reductions or increases shown and described. Thereductions and increases in cardiovascular control determinants havebeen provided here as examples and do not reflect an exhaustive list ofthe available adjustments in the cardiovascular determinants. Forexample, the afterload reductions shown include reductions of 10% and15%. The afterload reduction may range from approximately 0% toapproximately 50% and preferably ranges from approximately 10% toapproximately 20%. Additionally, in cases of sepsis or systemicinfection, the afterload may be maintained or increased.

Additionally, the exemplary strategies shown are not an exhaustive list.For example, FIGS. 26 and 27 are based solely on cardiac output 202,filling pressure 204, and systolic BP 226. Other strategies can beincluded and can be based on any combination of cardiovasculardeterminants. The strategies can be further based on clinical experienceand testing shown to bring cardiovascular functions closer to normalranges.

The controller 102 can include an electronic reporting module 142. Theelectronic reporting module 142 can be adapted to facilitate thedevelopment of a report 145 for record keeping or other purposes. Thereport 145 compiled by the electronic reporting module 142 can includethe clinical findings relating to patient condition and can also includethe intervention measures taken to adjust, stabilize, or otherwisechange the patient's condition. The electronic reporting module 142 canbe adapted to prompt the provider with one or more report input screens143 allowing the provider to select, confirm, modify, or otherwisetailor the report 145 and can also compile the report based on thisinput from the provider. The electronic reporting module 142 can beaccessible via one or more of the input devices of the providerinterface 104. That is, a menu button on the display 132 can beavailable for activating the electronic reporting module 142 and themenu button can be selected via a mouse, a touch screen, or any otherinput device. Other suitable activation elements and methods can beincluded such as a tab selection, a drop down box, and the like.

In a preferred embodiment, the electronic reporting module 142 can beadapted to compile an electronic and/or printed medical report.Preferably, the report 145 can include information relating to thehemodynamic management of a patient. Accordingly, as shown, for examplein FIG. 28, the electronic reporting module 142 can prompt the providerwith one or more report input screens 143. The screens 143 can promptthe provider for input relating to one or more of the clinical findingsobtained by the analysis module 136 and/or intervention measures takenby the provider. The findings on any particular screen or screens 143can include, the cardiac output, the filling pressures, the valvularstructure and function, and the contractile function. Additionally, thescreens can include intervention measures such as adjustments in theafterload, preload, heart rate, and contractility. Other findings orintervention measures can be included on the screens.

As shown, in FIG. 28 for example, the report input screen 143 can bedirected to the left-sided cardiac output. The screen may list a seriesof options suitable for the particular finding or intervention measurebeing addressed. Each of the options may include a short descriptivesentence representing a more detailed description of a clinical findingor an intervention measure. The selection of a report item can be in theform of radio buttons as shown or the selection can be check boxes,highlights, or other known selection types. The module 142 can beconfigured to allow only one selection or it can allow multipleselections for any given report item.

For each finding or intervention, the electronic reporting module 142can make an initial selection for reporting based on information fromthe analysis module 136. That is, for example, if the analysis module136 found that the LVOT was mildly decreased, the reporting module 142can make an initial selection for confirmation or modification by theprovider. If the provider has information indicating that the LVOT wassomething other than mildly decreased, the provider can select theappropriate finding. In the case of intervention measures, for example,if the clinical management module 140 suggested a preload reduction, thereporting module 142 may make an initial selection of preload reduction.However, if the actual intervention measure taken was not to adjust thepreload, the provider can change the selection to, for example, maintainpreload. In some embodiments, the module 142 can omit the initialselection and allow the provider to select the appropriate finding orintervention. It is noted, that the report input screens 143 can bedirected to clinical findings or intervention measures not obtained orsuggested, respectively, by the system. In these cases, the initialselection may be omitted. Where a common finding or intervention measureis known, the system can be configured to select the common finding ormeasure as a default for further review by the provider.

Upon selection or verification of the appropriate finding orintervention measure, the provider can be prompted to continue.Alternatively, the selection or verification can automatically cause themodule to continue. The provider can be prompted with additionaldisplays as required to select, verify, or otherwise obtain all of thenecessary information for the report 145. Once complete, the electronicreporting module 142 can compile a suitable report 145. For example, asshown in FIG. 29, the report 145 can include the detailed descriptionsof each of the clinical findings or intervention measures taken and canalso include a summary of the procedures.

The compiled report 145 can be in electronic form in a database reportformat, a word processing format, or another format. The report 145 canbe saved, printed, or otherwise stored as a record. The report 145 canbe formatted to comply with the medical record bylaws of a particularhealthcare facility or series of facilities. In addition, the report 145may be electronically coded according to Hospital Language (HL) protocoland sent out as a patient electronic medical record in a compatibleformat.

The controller 102 can include a DRG module 144. Many healthcare systemrevenues are determined by the Diagnosis Related Group (DRG) billingcodes resulting from a patient's visit to their facilities. Each DRGcode can be associated with a specific fee for which the hospital can bereimbursed relating to a specific rendered healthcare service. Most DRGcodes have two formats: a basic DRG and a DRG with complications andcomorbidities (CCs). DRG codes associated with clearly documented CCsare typically reimbursed at a higher rate than those without CCs (i.e.,a basic DRG). In the event that CCs are adequately identified anddocumented, reimbursement at the higher, DRG with CCs, rate is possible.In addition, identification of CCs at the time of admission of thepatient to the healthcare facility allows for the documentation ofcardiac comorbidities as Present On Admission (POA), as opposed to apost-operative complication diagnosis. This may reduce the likelihood oflower reimbursement that is now tied to the pay-for-performance Medicareand other insurance carrier programs. The device described herein allowsidentification of cardiovascular complications and comorbidities and assuch may allow for early identification of conditions and thus a higherrate of reimbursement.

The DRG module 144 may allow for the documentation of identified CCs.When activated by the healthcare provider, the DRG module 144 maydisplay a list of International Classification Diseases (ICD) codesdescribing cardiovascular CCs capable of being identified by the device.This list may be displayed on the display 132 as described above and asshown, by way of example, in FIG. 30. By selecting the most appropriatediagnosis (ICD codes) identified by the device, the end-user maygenerate a series of billing codes that may be used by the healthcarefacility to document the CCs. The billing codes may be documented in aseparate report called the DRG optimization report 147 as exemplified inFIG. 31. The report 147 may be printed on paper or written in anelectronic document. The report 147 may be added to the patient paper orelectronic medical record. The report 147 may also be sent by paper andor electronically to the healthcare facility billing and codingdepartment as a separate document from the medical record. This report147 may improve the capture of reimbursement for CCs by the healthcarefacility billers and coders for optimization of the patient's final DRGcode submitted to the insurance company for the services rendered. Thebilling codes generated may also be used in a separate document called aprofessional billing claim 149 as shown, by way of example, in FIG. 32.This document may allow for the healthcare provider to be paid for theprofessional services rendered with use of the device according to theCurrent Procedural Terminology (CPT) code fee schedule.

Referring now to FIGS. 33-36, the system methodology may be described.The system can function to acquire data from patients for use inmanaging the patient's condition and may further be used as a reportingtool. Using the patient interface 100, the system may be adapted toobtain patient information relevant to a particular procedure orcondition. The system can be further adapted to analyze and/or displaythat information. In addition, the system can suggest a suitableclinical strategy for managing the condition of the patient.

In a preferred embodiment, the probes 110 of the preferred patientinterface 100 described, can be used to obtain cardiovascular functioninformation from a patient. The probes 110 may obtain information basedupon their position on the patient. That is, certain positions canrepresent a cardiovascular window as described above and can lendthemselves toward collection of particular items of cardiovascularinformation. Accordingly, in a preferred embodiment, each probe 110 mayhave a particular set of data collection allocated to it based on theparticular window it is positioned in. However, depending on patientanatomy and other factors, a probe 110 in any given position may not beable to access the information typically available from its respectiveposition. In these cases, other positions can be used to compile themost complete set of data available.

More particularly, in a preferred embodiment, the basic sequence of dataacquisition may occur through the use of two probes 110. That is, insome embodiments, two probes 110 may be able to collect all of thecardiovascular function information by allocating some of theinformation to a first probe 110 and the remaining information to thesecond probe 110. In other embodiments, two probes 110 may not besufficient due to obstructions or other intervening causes. In stillother embodiments, additional probes 110 may be used to get additionalinformation by viewing particular structures from additional views. Insome embodiments, a single probe 110 may be sufficient. In otherembodiments, any number of probes 110 may be used.

Referring to FIG. 33, in a preferred embodiment, a first probe 110 canbe secured on a patient's chest at the parasternal window 300. Thisprobe 110 may be set by the patient interface module 134 to a first modefor a 2D black and white image. The patient interface module 134 canadjust the probe 110 to acquire a parasternal long-axis 2D imagingcross-section 302 of the heart for one or more heart beats. This blackand white 2D image clip can show the left ventricular heart musclecontracting and the mitral and aortic valves open and close. From thesame 2D cross-section, for example, without adjusting the view of theprobe 110, the mode of the first probe 110 can be changed to a secondmode and a color Doppler ROI box may be superimposed on the aortic 304and mitral 306 valves 2D live image. A clip of the data may be acquiredfor one or more heart beats. The color Doppler allows the assessment ofthe valves functionality by revealing the blood flow through the valves.Still using the first probe 110, additional data may be acquired byadjusting the probe 110 from the parasternal long-axis 2D imagingcross-section 302 to a parasternal short-axis 2D imaging cross-section308 for one or more heart beats. This short-axis probe view 308 canallow for the assessment of the left ventricular contractile functionand volume status.

Referring to FIG. 34, in a preferred embodiment, a second probe 110 canbe secured on the patient's chest at the apical window. This secondprobe 110 can be set by the patient interface module 134 to a first modefor a 2D black and white image. The patient interface module 134 canadjust the second probe 110 to acquire an apical four-chamber 2D imagingcross-section 312 for one or more heart beats. This 2D clip can evaluatethe right and left ventricular contractile function, as well as themitral and tricuspid valve. This additional 2D clip allows for thethree-dimensional heart structure to be assessed by a series oftwo-dimensional cross-sections by relying on view from several angles.The probe 110 can be set to a second mode for a color Doppler image ofthe mitral 313 and tricuspid valve 315. From the same 2D cross-section,for example, without adjusting the view of the probe 110, the mode ofthe first probe 110 can be changed to the third mode and a pulsed-wavespectral Doppler ROI box may be superimposed on the open mitral valve314 to measure the velocity of the red cells coming into the heartduring diastole. The data may be acquired and displayed on a spectralgraph showing velocity over time. The same pulsed-wave spectral DopplerROI box, for example, without changing the size of the ROI box, may besuperimposed on the right upper pulmonary vein 316. The velocity/timespectral graph of the pulmonary venous flow may then be acquired. Thepulsed-wave spectral Doppler ROI box may also be superimposed on theseptal or lateral side of the mitral valve annulus 318 to measure thetissue Doppler velocities of the left ventricle. Those three spectralDoppler measurements may then be used to assess the left ventriculardiastolic function and filling pressure. Also, a continuous wave Dopplersampling of the tricuspid regurgitation jet 319 peak velocity may bemade to estimate the right ventricular/pulmonary artery pulmonarypressure.

In a preferred embodiment, the patient interface module 134 can set thesecond probe 110 back to mode 1 and adjust the second probe 110 toacquire a 2D cross-section called an apical long-axis 320 for one ormore heart beats. From the same apical long-axis 2D cross-section,patient interface module 134 can set the second probe 110 to the 3^(rd)mode and a pulsed-wave spectral Doppler sampling area may besuperimposed on the left ventricular outflow tract (LVOT) 322 to measurethe velocity of the red cells being ejected out of the left heart over acardiac cycle (left-sided cardiac output). Additionally, acontinuous-wave spectral Doppler may be directed in the samelongitudinal axis to measure the velocity of the red cells at the levelof the aortic valve 324. This additional velocity allows the evaluationand quantification of aortic valve stenosis.

As mentioned, in some embodiments, the information gathered from thefirst and second probes 110 may be insufficient due to obstructed viewsor other intervening causes or additional views may be desired.Referring to FIG. 35, in some embodiments, a third probe 110 can besecured on the patient's upper abdomen under the right costal ridge inthe sub-costal window. The patient interface module 134 can set thethird probe 110 to a first mode for a 2D black and white image. Thepatient interface module 134 can adjust the third probe 110 to acquire asub-costal four chamber 2D imaging cross-section 326 for one or moreheart beats. This 2D clip may evaluate the right and left ventricularcontractile function, the size of the inferior vena cava as well as themitral and tricuspid valve. From the same 2D cross-section, the patientinterface module 134 can set the third probe 110 to a second mode and acolor Doppler region of interest (ROI) box may be superimposed on themitral valve 328 and the tricuspid valve 329. A clip of the data may beacquired for one or more heart beats. The color Doppler can allow theassessment of the mitral and tricuspid valve functionality. In thepresent embodiment, and still using the third probe 110, the patientinterface module 134 can set the third probe 110 to a first mode. Thethird probe 110 can be adjusted for a sub-costal right ventricularinflow-outflow 2D imaging cross-section 331, which may be acquired forone or more heart beats. This allows the evaluation of the right heartstructures and function. From the same 2D cross-section, the patientinterface module 134 can set the third probe 110 to a third mode and apulsed-wave spectral Doppler sampling area may be superimposed on theright ventricular outflow tract (RVOT) 332 to measure the velocity ofthe red cells being ejected out of the right heart over a cardiac cycle(right-sided cardiac output). Still using the third probe 110, asub-costal LV short-axis 2D imaging cross-section 330 may be acquiredfor one or more heart beats. This allows the assessment of the leftventricular contractile function and volume status.

When the ultrasound-generated data points from the second probe 110regarding the left heart cardiac output are inadequate or whenadditional views are desired, the user may rely on a fourth probe 110 toacquire a continuous-wave spectral Doppler tracing signal of either theascending aorta or the distal aortic arch or the descending aorta.

When the ultrasound-generated data points from the first, second, third,or fourth probes 110 are inadequate or as an additional available set ofdata, a fifth probe 110 can be used. Referring to FIG. 36, the fifthprobe 110 may be positioned in the mid-esophageal window and may acquireultrasound-generated data points from behind the heart (inside thebody). The fifth probe 110 may acquire a mid-esophageal four chamber 2Dimaging cross-section 334 for one or more heart beats. This 2D clipevaluates the right and left ventricular contractile function, as wellas the mitral and tricuspid valves. From the same 2D cross-section, acolor Doppler region of interest (ROI) box may be superimposed on themitral 336 and tricuspid 338 valves 2D live image. A clip of the datamay also be acquired for one or more heart beats. The color Dopplerallows the assessment of the mitral and tricuspid valve functionality.From the same 2D cross-section, a pulsed-wave spectral Doppler samplingarea may be superimposed on the opened mitral valve 340 to measure thevelocity of the red cells coming into the heart during diastole. Thedata may be acquired and displayed on a spectral graph showing velocityover time. Then, the same pulsed-wave spectral Doppler sampling area maybe superimposed on the left upper pulmonary vein 342. The velocity/timespectral graph of the pulmonary venous flow may then be acquired. Thepulsed-wave sampling Doppler may then be superimposed on the septal orlateral side of the mitral valve annulus 344 and may measure the tissueDoppler velocities of the left ventricle. Those three spectral Dopplermeasurements may be used to assess the left ventricular diastolicfunction and filling pressure. A continuous wave Doppler sampling of thetricuspid regurgitation jet 339 peak velocity may be made to estimatethe right ventricular/pulmonary artery pulmonary pressure.

The method resulting from the use of the described device may bereferred to as Echocardiography-Guided Anesthesia Management (EGAM)and/or Echocardiography-Guided Hemodynamic Management (EGHEM).EGAM/EGHEM may automatically acquire ultrasound-generated real-time datapoints like cardiac output and filling pressures to assess, manage,modify and optimize the patient cardiac preload, afterload, heart rateand contractility. Two clinical case studies were conducted as describedbelow.

CLINICAL EXAMPLE 1 Step 1: Patient Selection

Male patient, 81 year old, scheduled for a left hip pinning for afracture repair. He weighs 89 Kg and is 178 cm tall. His BSA is 2.1 m2.The patient has long-standing hypertension, and has a history oftransmural myocardial infarction (MI) 4 years prior. The patient has alimited functional capacity of approximately 5 METs with symptoms ofshortness of breath (SOB), occasional chest pain stable for last twoyears, and hip pain. His medication includes an ACEI and a beta-blocker.

Step 2: Baseline Pre-Operative Assessment

The device and methods previously described in this document wereapplied to this patient. This process was performed at bedside beforeanesthesia was provided. The process was pain free and took a fewminutes to complete. Below is the summary of the information provided bythe device:

Baseline Vital Signs:

-   -   a. blood pressure (BP)=160/85 mmHg,    -   b. heart rate (HR)=82 bpm, regular,    -   c. SpO₂=92% room air.

Primary EGAM/EGEM Findings:

-   -   a) Reduced cardiac output: LVOT diameter is 2 cm, LVOT        VTI=12 cm. CO: 3.1 L/min, CI=1.5 Lmin/m²    -   b) LV Filling pressures are elevated based on a pseudonormal LV        filling pattern, a pulmonary venous flow diastolic dominant and        an E/e′ ratio of 25.

Secondary EGAM/EGHEM Findings;

-   -   a) Mitral valve: mild regurgitation.    -   b) Aortic valve: sclerosis without significant stenosis.    -   c) LV contractile function: moderately reduced with a visually        estimated ejection fraction (EF) at 30%.

Step 3: Management Strategies

The patient presents a low cardiac output, high filling pressure, highsystemic blood pressure, reduced LV contractile function and mild mitralregurgitation. The suggested EGAM/EGHEM strategy based on FIG. 26recommendation is to reduce the afterload and blood pressure by 15% andlimit all IV intakes only to keep the vein open. A general anesthetic isplanned with IV induction agents and maintenance done with aninhalational agent. If required, the basal IV intake needs are 65ml/hour. The EGAM/EGHEM data will be controlled 5 minutes afterinduction.

Step 4: Ongoing Intra-Operative Assessment

The following table summarizes the intra-operative findings andinterventions

Cardiac Filling Blood LV Timeline output pressure pressure contractilityInterventions Baseline 3.1 High 160/85 EF = 30% Limit preload L/min E/e′= 25 Reduce to systolic BP to 136 5 min post- 3.5 High 132/78 No changeLimit preload induction L/min E/e′ = 20 Reduce BP to 112 Control #1 3.8Normal 108/72 Mild increase Maintain 15 min later L/mi E/e′ = 13 basalneeds Reduce BP to 98 Control #2 4.2 Normal 96/68 No change Maintain 15min later L/min E/e′ = 12 basal needs Reduce BP to 90 Control #3 4.4Normal 84/62 EF = 35% Give IV bolus 7 min later L/min E/e' = 10 100 mlLimit afterload reduction Control #4 4.5 Normal 92/64 No change Maintain5 min later L/min E/e′ = 14 basal needs Maintain afterload Control #54.3 Normal 96/68 No change Maintain 15 min later L/min E/e′ = 12 basalneeds Maintain afterload Control #6 3.8 Normal 145/72 No change MaintainIn recovery L/min E/e′ = 14 basal needs room Reduce BP to low 90's

Follow-Up Events

The case lasted for about 1 hour. The patient received a total of 250 mlof IV fluid. The urine output during the procedure was 150 ml. The bloodloss was estimated at 150 ml. The SpO2 on room air in recovery room aswell as post-op day 1 was 98%. The patient remained comfortable. Thepost-operative course included an increase of blood pressure medicationand the addition of a low dose diuretic, as well as a reduced salt andfluid intake. The target systolic BP was in the 90's. The dischargeweight was 83 kg, the CO was 4.3 L/min, BP=96/72. The patient toleratedthose changes well and reported no orthostatic hypotension, no stroke,and no changes of renal function. He was still alive and doing well at30 days post-op and did not require readmission during the same periodand had no new cardiac events.

The device effectively identified that the patient was in a noncompensated state of congestive heart failure with reduced cardiacoutput and ventricular contractility. The clinical strategy used toaddress those issues was significantly different than what the standardpre-operative evaluation was dictating because the supplementalinformation provided by the device suggested a completely oppositestrategy. By using the invention, the health care provider had access tomore accurate information, was able to provide better care to thepatient and reduce the risk of post-operative cardiovascularcomplications.

Case Study 2 Step 1: Patient Selection

Female patient, 82 year old, scheduled for elective, righthemicolectomy. She weights 79 Kg and is 160 cm tall. Her BSA is 1.9 m2.Patient has medically treated hypertension with a hydrochlorothiazide.She stopped smoking two year ago but has a 20 pack-years history. She iscomplaining of a progressive shortness of breath and reduction of herfunctional capacity over the last year, currently estimated at 6 or 7METs. She has no chest pain or palpitations.

Step 2: The Baseline Pre-Op Assessment

The device and methods previously described in this document wereapplied to this patient. This process was performed at bedside beforeanesthesia was provided. The process was pain free and took a fewminutes to complete. Below is the summary of the information provided bythe device:

Baseline Vital Signs:

-   -   a. blood pressure (BP)=168/92 mmHg,    -   b. heart rate (HR)=70 bpm, regular,    -   c. SpO₂=90% room air.

Primary EGAM/EGHEM Findings:

-   -   a) Normal cardiac output: LVOT diameter is 2 cm, LVOT VTI=22 cm.        CO: 4.8 L/min, CI=2.5 L/min/m²    -   b) LV Filling pressures are elevated based on a restrictive        filling pattern, a pulmonary venous flow diastolic dominant and        an E/e′ ratio of 35.

Secondary EGAM/EGHEM Findings:

-   -   a) Mitral valve: mild to moderate regurgitation.    -   b) Aortic valve: sclerosis with mild stenosis.    -   c) LV contractile function is normal with a visually estimated        EF at 60%

Step 3: Management Strategies

The patient presents a normal cardiac output, high filling pressure,high systemic blood pressure, a normal LV contractile function, mild tomoderate mitral regurgitation and mild aortic stenosis. The suggestedEGAM/EGHEM strategy based on FIG. 27 is to reduce the afterload andblood pressure by 15% and limit all IV intakes only to keep the veinopen. A general anesthetic is planned with IV induction agents andmaintenance done with total intravenous anesthetics agents. If required,the basal IV intake needs are 60 ml/hour. The EGAM/EGHEM data will becontrolled 5 minutes after induction.

Step 4: Ongoing Intra-Operative Assessment

The following table summarizes the intra-operative findings andinterventions

Cardiac Filling Blood LV Timeline output pressure pressure contractilityInterventions Baseline 4.8 High 162/92 EF = 60% Limit preload L/min E/e′= 35 Reduce to systolic BP to 145 5 min post- 5.1 High 141/72 No changeLimit preload induction L/min E/e′ = 30 Reduce BP to 120 Control #1 5.5High 128/67 No change Limit preload 15 min later L/min E/e′ = 26 ReduceBP to 110 Control #2 5.3 High 105/59 No change Limit preload 15 minlater L/min E/e′ = 24 Reduce BP to 95 Control #3 5.4 High 92/55 Nochange Limit preload 15 min later L/min E/e' = 22 Maintain afterloadControl #4 5.2 Normal 96/58 No change Maintain 15 min later L/min E/e′ =14 basal needs Maintain afterload Control #5 5.3 Normal 98/64 No changeMaintain 15 min later L/min E/e′ = 12 basal needs Maintain afterloadControl #6 4.8 Normal 78/48 No change Give IV bolus 15 min later L/minE/e′ = 10 of 250 ml Maintain afterload Control #7 5.1 Normal 105/74 Nochange Maintain In recovery L/min E/e′ = 14 basal needs room Reduce BPto 90's

Follow-Up Events

The case lasted for about 2 hours. The patient received a total of 300ml of IV fluid. The urine output during the procedure was 450 ml. Theblood loss was estimated at 250 ml. The SpO2 on room air in recoveryroom was 97%. The patient remained comfortable. The post-operativecourse included an increase of his existing blood pressure medicationand the addition of an ACEI, as well as low sodium diet. The targetsystolic BP was in the 90's. The discharge weight was 72 kg, the CO was5.2 L/min, BP=100/68. The patient tolerated those changes well andreported no orthostatic hypotension, no stroke, and no changes of renalfunction. She was still alive and doing well at 30 days post-op and didnot require readmission during the same period and no new cardiacevents.

The device effectively identified that the patient was in a noncompensated state of congestive heart failure with normal cardiac outputand ventricular contractility but very high filling pressures. Theclinical strategy used to address those issues was significantlydifferent than what the standard pre-operative evaluation was dictatingbecause the supplemental information provided by the device suggested acompletely opposite strategy. By using the invention, the health careprovider had access to more accurate information, was able to providebetter care to the patient and reduce the risk of post-operativecardiovascular complications.

As shown and described regarding FIGS. 37-42, the system may performseveral methods. The steps included in any of the described methods maybe completed in any order and any or all of the steps may be included.

Referring to FIG. 37, a method of is shown including at box 400,Generate ultrasound data point, at box 402, Interpret ultrasound datapoints provided by each of the probes 110, at box 404, Rely on a systemof first order and second order data points to suggest an optimalclinical strategy, at box 406, Output the suggested strategy to adisplay wherein the strategy includes modification (increase, reduce ormaintain) of one or more cardiovascular determinants such as preload,afterload, heart rate, and ventricular contractility, at box 408,Display a list of possible clinical findings, at box 410, Promptend-user to select from a list, at box 412, Receive input from end-user,and at box 414, Generate a Final Report.

In addition, the method may include at box 416, Prompt user with a listof ICD codes for selection based on output from system analysis, at box418, Receive input from end-user regarding ICD codes, at box 420,Prepare DRG optimization report, and at box 422, prepare a professionalbilling claim.

Referring to FIG. 38, a method is shown including, at box 424, obtainingultrasound information regarding a condition of the patient from anultrasound probe, at box 426, communicating the ultrasound informationto a controller in communication with the ultrasound probe, at box 428,employing the controller to develop a determinant from the ultrasoundinformation reflecting the condition of the patient, and at box 430,providing on an output device in communication with the controller aclinical management strategy based on the determinant.

Referring to FIG. 39, a method is shown including, at box 432, receivingultrasound information from a patient interface, the patient interfacebeing adapted to obtain ultrasound information related to cardiovascularfunction status of the patient, at box 434, processing the ultrasoundinformation to determine the cardiovascular function status of thepatient, and at box 436, sending the status to a clinical managementmodule for the development of a clinical strategy.

Referring to FIG. 40, a method is shown including, at box 438, comparinga first order data point to a plurality of categories, wherein the firstorder data point is associated with ultrasound information, at box 440,assigning a category from the plurality of categories to the first orderdata point based on which category of the plurality of categories, thefirst order data point falls, at box 442, selecting a recommendedintervening measure based on the assigned category, and at box 444,presenting the recommended intervening measure on a display.

Referring to FIG. 41, a method is shown including, at box 446,positioning ultrasound probes on a patient, the ultrasound probes beingin communication with a controller, at box 448, using an input device toinstruct the controller to obtain cardiovascular function informationfrom the patient via the ultrasound probes, at box 450, reviewing asuggested clinical management strategy, the strategy including arecommended intervening measure and being based upon the ultrasoundinformation, and at box 452, deciding whether to conduct the recommendedintervening measure, a different intervening measure, or no interveningmeasure.

Referring to FIG. 42, a method is shown including, at box 454,monitoring a patient via ultrasound and generating information with theultrasound and based upon the information, recording a clinical findingand recommending and recording an intervening measure, at box 456,displaying a list of clinical findings including the clinical findingand related clinical findings, at box 458, prompting a user to selectfrom the list of clinical findings, at box 460, displaying a list ofintervening measures including the intervening measure and relatedintervening measures, at box 462, prompting the user to select from thelist of intervening measures, and at box 464, compiling a reportincluding the selected clinical finding and the selected interveningmeasure.

While the term provider has been used throughout the specification, itis to be understood that this is not limited to a licensed medicaldoctor, physicians assistant, nurse practitioner, and the like. Instead,provider can by any user of the system. Preferably, the provider issomeone working under the guidance of a licensed practitioner and whounderstands cardiovascular function so as to provide suitable input tothe system.

Additionally, while the phrase black and white has been used withreference to certain ultrasound images, it is to be understood thatblack and white means a non-color image. That is, an image that does notaccurately depict the colors of the displayed elements, but ratherdisplays similar but varying tones of several elements to make themdistinguishable from one another. For example, black and white, sepia,orange, or green colors may be included within the black and whitedescription.

Additionally, the categories of cardiovascular determinants are not tobe limited to those categories disclose. More or less precise categoriescould be used and the image clip databases and categories can beadjusted accordingly. For example, with respect to contractile function,rather than using hyperdynamic, normal, moderately reduced, and severelyreduced as categories, the categories could instead be normal andabnormal. The contractile function image clip database can be adjustedto include normal clips and abnormal clips and to include only twocategories in lieu of four. This holds true for all of the image clipdatabases and the associated categories.

Although the present invention has been described with a certain degreeof particularity, it is understood the disclosure has been made by wayof example, and changes in detail or structure may be made withoutdeparting from the spirit of the invention as defined in the appendedclaims.

What is claimed is:
 1. A system for hemodynamically managing a patient,the system comprising: a) a patient interface configured to capturefirst cardiac image data regarding the patient; b) a database comprisingsecond cardiac image data stored in the database; and c) a controller incommunication with the database and patient interface, the controllerconfigured to compare the first cardiac image data to the second cardiacimage data, the controller categorizing the first cardiac image dataaccording to a category of the second cardiac image data the firstcardiac image data most closely resembles.
 2. The system of claim 1,wherein the controller identifies an intervening hemodynamic treatmentmeasure correlated with the category of the second cardiac image datathe first cardiac image data most closely resembles.
 3. The system ofclaim 2, further comprising a provider interface configured to displaythe intervening hemodynamic treatment measure.
 4. The system of claim 2,wherein the intervening hemodynamic treatment measure is correlated inthe database with the category of the second cardiac image data thefirst cardiac image data most closely resembles.
 5. The system of claim2, wherein the intervening hemodynamic treatment measure comprises atleast one of the following: reducing afterload; maintaining afterload;reducing preload; maintaining preload; increasing preload; or inotropicsupport.
 6. The system of claim 1, wherein the category of the secondcardiac image data is associated with at least one of the followinghemodynamic conditions: low cardiac output; normal cardiac output; lowleft ventricular filling pressure; normal left ventricular fillingpressure; or high left ventricular filling pressure.
 7. The system ofclaim 1, wherein the category of the second cardiac image data isassociated with at least one of the following hemodynamic conditions:contractile function, valvular function; left ventricular diastolicfunction; left ventricular filling pressure; pulmonary artery pressure;or cardiac output.
 8. The system of claim 1, wherein the patientinterface comprises an ultrasound probe and the first cardiac image datacomprises a cardiac ultrasound image.
 9. The system of claim 8, whereinthe second cardiac image data comprises a cardiac ultrasound image. 10.The system of claim 1, wherein the second cardiac image data comprises acardiac ultrasound image.
 11. The system of claim 1, further comprisingimage recognition software used to analyze the first cardiac image data.12. The system of claim 1, wherein the second cardiac image datacomprises video images.
 13. The system of claim 12, wherein the videoimages comprise a video loop.
 14. The system of claim 1, wherein thesecond cardiac image data comprises a still video image.
 15. The systemof claim 1, wherein the patient interface comprises multiple ultrasoundprobes configured to be attached to the patient at differentspaced-apart cardiac ultrasound windows of the patient.
 16. A method forhemodynamically managing a patient, the method comprising: a) capturingvia a patient interface first cardiac image data regarding the patient;b) accessing second cardiac image data that is stored in a database; c)comparing via a controller in communication with the database the firstcardiac image data to the second cardiac image data; and d) categorizingvia the controller the first cardiac image data according to a categoryof the second cardiac image data the first cardiac image data mostclosely resembles.
 17. The method of claim 16, further comprisingidentifying via the controller an intervening hemodynamic treatmentmeasure correlated with the category of the second cardiac image datathe first cardiac image data most closely resembles.
 18. The method ofclaim 17, further comprising displaying on a provider interface theintervening hemodynamic treatment measure.
 19. The method of claim 17,wherein the intervening hemodynamic treatment measure is correlated inthe database with the category of the second cardiac image data thefirst cardiac image data most closely resembles.
 20. The method of claim17, wherein the intervening hemodynamic treatment measure comprises atleast one of the following: reducing afterload; maintaining afterload;reducing preload; maintaining preload; increasing preload; or inotropicsupport.
 21. The method of claim 16, wherein the category of the secondcardiac image data is associated with at least one of the followinghemodynamic conditions: low cardiac output; normal cardiac output; highcardiac output; low left ventricular filling pressure; normal leftventricular filling pressure; or high left ventricular filling pressure.22. The method of claim 16, wherein the category of the second cardiacimage data is associated with at least one of the following hemodynamicconditions: contractile function; valvular function; left ventriculardiastolic function; left ventricular filling pressure; pulmonary arterypressure; or cardiac output.
 23. The method of claim 16, wherein thepatient interface comprises an ultrasound probe and the first cardiacimage data comprises a cardiac ultrasound image.
 24. The method of claim23, wherein the second cardiac image data comprises a cardiac ultrasoundimage.
 25. The method of claim 16, wherein the second cardiac image datacomprises a cardiac ultrasound image.
 26. The method of claim 16,wherein the comparison of step c) comprises using image recognitionsoftware to analyze the first cardiac image data.
 27. The method ofclaim 16, wherein the second cardiac image data comprises video images.28. The method of claim 27, wherein the video images comprise a videoloop.
 29. The method of claim 16, wherein the second cardiac image datacomprises a still video image.
 30. The method of claim 1, wherein thepatient interface comprises first and second ultrasound probes andwherein the method further comprises attaching the first ultrasoundprobe to the patient at a first cardiac ultrasound window of the patientand attaching the second cardiac ultrasound probe to the patient at asecond cardiac ultrasound window, the first and second cardiacultrasound windows being spaced-apart from each other, and the first andsecond ultrasound probes being attached to the patient over a commontime period.
 31. The method of claim 30, wherein the first cardiacultrasound window comprises one of a transthoracic parasternal window, atransthoracic apical window, a sub-costal window, or a suprasternalnotch window, and the second cardiac ultrasound window comprises one ofthe transthoracic parasternal window, the transthoracic apical window,the sub-costal window, or the suprasternal notch window that is not thefirst cardiac ultrasound window.